Dongcheng Pharmaceutical Group Co., Ltd. announced the progress of its share buyback program, approved by the board on December 31, 2025. As of May 31, 2026, the company repurchased 6,367,599 shares, accounting for 0.77% of its total share capital, at a total cost of approximately RMB 87.17 million. The buyback is in compliance with relevant regulations and the company's established plan.
Summary generated by AI · Always verify with source document
Dongcheng Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, without any false records, misleading statements, or significant omissions.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.